Estrogens promote cell proliferation and metastases in several human cancers. Here, we describe a different action of estrogens likely to contribute to tumor development-blocking immunosurveillance. In breast cancer cells, increasing concentrations of estrogen induce increasing levels of the granzyme B inhibitor, SerpinB9/proteinase inhibitor 9 (PI-9) and progressively block cell death induced by NK92 natural killer (NK) cells, but do not block killing by a second NK cell line, NKL cells. RNA interference knockdown of PI-9 abolishes estrogen's ability to block NK92 cell-induced cytotoxicity. Expressing elevated levels of estrogen receptor a (ERa) increases the induced level of PI-9, and makes tamoxifen (TAM), but not raloxifene or ICI 182,780, a potent inducer of PI-9. At elevated levels of ERa, induction of PI-9 by estradiol or TAM blocks killing by both NK92 and NKL cells. When the Erk pathway is activated with epidermal growth factor, the concentration of estrogen required to induce a protective level of PI-9 is reduced to 10 pM. Elevated concentrations of estrogen and ER may provide a dual selective advantage to breast cancer cells by controlling PI-9 levels and thereby blocking immunosurveillance. Expressing elevated levels of ERa reveals a potentially important difference in the effects of TAM, raloxifene and ICI 182,780 on immunosurveillance in breast cancer.
Introduction
Clinical data and studies in mice show that the immune system recognizes and eliminates early-stage developing tumors and acts as an extrinsic tumor suppressor -a process sometimes referred to as immunosurveillance (Dunn et al., 2004a, b) . Immunosurveillance results primarily from apoptosis of neoplastic cells induced by natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). These cytolytic lymphocytes (CLs) use perforin and granzyme-containing granules, and to a lesser extent the Fas/Fas ligand pathway, to induce lysis of target cells. Granzyme B (GrB), is thought to play a leading role in granzyme-mediated cytotoxicity with a lesser role for granzyme A (GrA) (Russell and Ley, 2002; Lieberman, 2003) . On recognizing a nearby target cell, the granule proteins are released from a complex with serglycin and the granule complex enters the target cells via endocytosis. Release of GrB and other granzymes from the endosome is facilitated by perforin. GrB induces apoptosis through several pathways, including cleavage and activation of the pro forms of effector caspases and direct cleavage of caspase and novel non-caspase substrates, such as ROCK II kinase (Andrade et al., 1998; Thomas et al., 2000; Russell and Ley, 2002; Goping et al., 2003; Lieberman, 2003; Sebbagh et al., 2005) The serine proteinase inhibitor, SerpinB9/proteinase inhibitor 9 (PI-9) is the only known intracellular human inhibitor of GrB (Bird et al., 1998) . Overexpression and knockout studies of the related mouse GrB inhibitor, serine protease inhibitor 6 (SPI-6) show that increasing expression of SPI-6 prolongs the life span of CD8 þ memory T lymphocytes, whereas loss of SPI-6 causes severe damage to CTLs and impairs their ability to lyse cells expressing pathogens (Phillips et al., 2004; Zhang et al., 2006) . Consitutive high level expression of PI-9 reduces the ability of NK cells and CTLs to kill tumor cells (Medema et al., 2001; Bots et al., 2006a) . High levels of PI-9 are associated with poor prognosis in anaplastic large B-cell lymphoma, and in melanoma patients following immunotherapy (ten Berge et al., 2003; van Houdt et al., 2005) . Thus, PI-9 or SPI-6 level influences the ability of immune cells to target and kill tumor cells.
Inflammation modulators, including IL-1b and lipopolysaccharide, acting through an upstream activator protein-1 site and two nuclear factor-kB sites induce PI-9 (Kannan-Thulasiraman and Shapiro, 2002). Using human liver biopsy specimens and HepG2ER7, human hepatoma cells (HepG2 cells stably transfected to restore expression of estrogen receptor a (ERa)), we showed that PI-9 is a primary estrogen-inducible gene (Kanamori et al., 2000) . Estrogen-ER complex activates PI-9 gene transcription through binding of two ER dimers to a downstream estrogen responsive unit (ERU) that binds ER in chromatin immunoprecipitations. In electrophoretic mobility shift assays increasing levels of 17b-estradiol (E 2 )-ERa resulted in increased binding of the second ER dimer (Krieg et al., 2001 (Krieg et al., , 2004 . Induction of PI-9 by interferon (IFN)-g, or by estrogen, partially protects liver cells against cytolysis induced by CLs (Barrie et al., 2004; Jiang et al., 2006) .
Estrogens, acting via ER, exert stimulatory effects on breast cancer. The selective estrogen receptor modulator (SERM), tamoxifen (TAM), which acts in part by antagonizing the stimulatory effects of estrogens, is widely used in endocrine therapy for breast cancer. (Lewis and Jordan, 2005; Yager and Davidson, 2006) . ERa is upregulated in many breast cancers (Riera et al., 1999; Gritzapis et al., 2003) . Tumors expressing the highest levels of ERa exhibit poor prognosis and reduced sensitivity to TAM (Thorpe et al., 1993; Romain et al., 1994; Lewis and Jordan, 2005) .
Estrogen concentration, the nature of the ER ligand, ER concentration and activation of the ER by kinasebased signaling pathways work collectively to influence expression of estrogen-regulated genes in cancer cells. Here we examined the interplay between these factors in controlling the level of PI-9 in breast cancer cells and thereby regulating their susceptibility to NK cellmediated cytolysis. Our studies suggest concentrations of estrogen, ER and epidermal growth factor/epidermal growth factor receptor (EGF/EGFR) intersect at the level of PI-9 induction and thereby confer a selective advantage to breast cancer cells by interfering with immunosurveillance.
Results PI-9 is induced by E 2 and by 4-hydroxyTAM in MCF-7 breast cancer cells To test whether PI-9 regulation by estrogen extends beyond liver cells to breast cancer cells, we analysed PI-9 expression in the widely used model for ER action in breast cancer, Michigan Cancer Foundation (MCF)-7 human breast cancer cells and in a tetracycline-inducible MCF-7 model in which doxycycline (Dox) induces overexpression of ERa (Fowler et al., 2004 (Fowler et al., , 2006 .
In MCF-7 cells, PI-9 messenger RNA (mRNA) was strongly and rapidly induced by E 2 (Figure 1a) . A doseresponse curve for induction of PI-9 mRNA by E 2 Figure 1 Estrogen induces PI-9 mRNA and protein in MCF-7 cells. (a) Quantitative RT-PCR of the time course of E 2 induction of PI-9 mRNA in MCF-7 cells. QRT-PCR was carried out as described in Materials and methods. (b) Dose-response curve for E 2 induction of PI-9 mRNA. RNA was isolated 4 h after addition of E 2 to the cell culture medium. (c) Effect of SERMs on induction of PI-9 mRNA. The medium contained ethanol vehicle (control) or 10 nM E 2 . The SERMs, OHT, raloxifene (RAL) and ICI 182, 780 (ICI) were present at 1 mM in the absence or presence of 10 nM E 2 . Cells were harvested at 4 h. (d) Western blot of the time course of E 2 induction of PI-9 protein in MCF-7 cells. Western blotting was carried out as described in Materials and methods. The data in (a-c) and all quantitative data in subsequent figures represent the mean7s.e.m. for at least three separate experiments.
Induction of PI-9 progressively blocks immunosurveillance X Jiang et al showed B15-fold induction (B30% of maximum) at 10 pM E 2 and maximum (B50-fold) induction of PI-9 mRNA at 100 pM E 2 (Figure 1b) . We compared the effects of E 2 and several SERMs on the induction of PI-9 mRNA. 4-Hydroxytamoxifen (OHT) induced PI-9 mRNA B10-fold. Raloxifene and ICI 182,780 did not induce PI-9 mRNA and when present in excess blocked the E 2 induction of PI-9 mRNA (Figure 1c ). This indicates that induction of PI-9 mRNA by E 2 is mediated by binding of E 2 to ER. Western blots showed that induction of PI-9 mRNA by E 2 resulted in an increase in the level of PI-9 protein over 4-24 h (Figure 1d ). E 2 protects MCF-7 cells against NK cell-mediated lysis As human NK cells and CTLs kill target cells by similar mechanisms (Russell and Ley, 2002; Lieberman, 2003) , and established lines of human CTLs are not available, we identified lines of human NK cells that can lyse MCF-7 cells. Consistent with previous reports that the Fas-Fas ligand pathway of cell death is not functional in MCF-7 cells (Lamboley et al., 2000) , anti-Fas activating antibody induced apoptosis of HepG2ER7 cells (Jiang et al., 2006) , but had no effect on MCF-7 cells (data not shown). As concanamycin A, a specific inhibitor of the granzyme pathway (Kataoka et al., 1996) , abolished the ability of NK cells to kill MCF-7 cells (Supplementary Figure S1 ), the MCF-7 cells were being killed through the granzyme pathway.
Using a time-resolved fluorescence assay that detects release of a fluorescent substrate from cells that lose membrane integrity (Blomberg et al., 1996) , estrogen treatment for 24 h dramatically reduced cell death induced by NK92 cells (Figure 2 ). These results were confirmed using the classical RNAi knockdown of PI-9 abolishes E 2 protection of MCF-7 cells from NK cell-induced cytotoxicity PI-9 inhibits GrB and the NK cells use the granzyme pathway to kill target cells. However, the diverse effects of estrogens raise the possibility that other actions of estrogen might be responsible for blocking NK cellinduced cytotoxicity. To evaluate the role of PI-9 in estrogen-mediated protection against NK cell-induced cytotoxicity, we used RNA interference (RNAi) to knock down PI-9 expression. We transfected MCF-7 cells with a PI-9-specific small-interfering RNA (siRNA), or with a control pGL3 luciferase siRNA in the presence or absence of E 2 . Western blot analysis showed that the PI-9 siRNA blocked induction of PI-9 protein by E 2 (Figure 3a , compare pGL3 þ E 2 with PI-9 þ E 2 ). As a control, we transfected MCF-7 cells with pGL3 siRNA and maintained them in medium containing or lacking E 2 . At all ratios of effector NK92 cells to target MCF-7 cells, the cells transfected with pGL3 siRNA and incubated in medium containing E 2 efficiently blocked NK92-induced cell lysis. Knockdown of PI-9 with PI-9-specific siRNA abolished the ability of E 2 to block NK92 cell-induced killing (Figure 3b ). These Cytotoxicity assays were performed as described in Materials and methods. Figure 3 RNAi knockdown of PI-9 blocks estrogen protection against NK cell-mediated cytotoxicity. (a and b) MCF-7 cells were transfected with the control pGL3 luciferase siRNA, or with the PI-9 siRNA. After 24 h, ethanol vehicle or E 2 was added and the cells were maintained for an additional 24 h and either harvested for Western blotting using antibodies to PI-9 and the internal standard calnexin (a) or incubated with the indicated ratios of effector NK92 cells to MCF-7 target cells and assayed for cytoxicity using the time-resolved fluorescence assay (b) (filled and open bars, pGL3 siRNA À and þ E2, respectively; diagonal bars, PI-9 siRNA þ E 2 ). Western blotting and the time-resolved fluorescence cytotoxicity assay are described in Materials and methods.
Induction of PI-9 progressively blocks immunosurveillance X Jiang et al data demonstrate that estrogen's ability to block NK cell-mediated cytolysis of MCF-7 cells derives from its ability to induce PI-9.
Picomolar concentrations of E 2 and Erk activation efficiently induce PI-9 and block NK92 cell-induced cytotoxicity In dose-response studies, PI-9 mRNA is partially induced by 10 pM E 2 and fully induced by 100 pM E 2 (Figure 1b) . Western blots showed that PI-9 was strongly induced by 50 pM E 2 and approached the level of PI-9 seen with 100 pM and 1 nM E 2 (Figure 4a ). We therefore tested the effect of a range of E 2 concentrations (50 pM, 100 pM and 1 nM) on NK92 cell-induced cytotoxicity. Inducing PI-9 with 50 pM E 2 largely blocked NK92 cell-induced killing of MCF-7 cells ( Figure 4b ). As the circulating concentration of estrogen in postmenopausal women is B50 pM (Meldrum et al., 1981; Lonning et al., 1997) , the low concentration of estrogen in postmenopausal women is sufficient to efficiently induce PI-9 and largely block the ability of NK92 cells to kill MCF-7 breast cancer cells. ER-mediated transactivation is stimulated by EGF activation of the Erk signaling pathway (Levin, 2003) . EGF transiently increased the fold induction of PI-9 mRNA by E 2 at 2 h postexposure, but not at 4 h. The Erk pathway inhibitor U0126 abolished the stimulatory effect of EGF and reduced the fold induction of PI-9 below the level seen with E 2 alone (Supplementary Figure S3A) . Western blot analysis showed that PI-9 induction by a subsaturating concentration of E 2 (10 pM) was enhanced by addition of EGF (Supplementary Figure S3B ). EGF did not influence NK cell-induced cytolysis and 10 pM E 2 alone did not induce PI-9 well enough to protect against NK92 cell-induced cytolysis. However, 10 pM E 2 plus EGF enhanced induction of PI-9 and largely blocked NK92-induced cell killing (Supplementary Figure S3C) . Enhancing ER-mediated transactivation by activating an oncogenic signal-transduction pathway reduces the concentration of estrogen required to induce a protective level of PI-9.
The SERM raloxifene does not induce PI-9 and in 100-fold excess blocked the E 2 induction of PI-9 mRNA (Figure 1c) . Consistent with this data, raloxifene, in 100-fold excess, blocked the ability of E 2 to protect the cells against NK92-induced killing (Supplementary Figure S4) . Induction of PI-9 by OHT to B20% of maximum ( Figure 1c) is not sufficient to protect cells from killing by NK92 cells (Supplementary Figure S4) . The average circulating concentrations of TAM (1 mM) and OHT (100 nM) in women being treated with TAM (Kisanga et al., 2004) are sufficient to block the effect of E 2 to prevent NK cell-induced killing (Supplementary Figure S4) .
OHT induces high levels of PI-9 in MCF-7 cells expressing high ERa levels and blocks NK92 cell-induced cytotoxicity ER levels increase in postmenopausal women and can be high in breast cancer cells relative to normal mammary tissue. We tested whether elevated levels of ER alter regulation of PI-9 and inhibition of apoptosis. A tetinducible MCF-7 cell model, termed ERaHA cells, was utilized to increase ER expression (Fowler et al., 2004) . As expected, E 2 strongly induced PI-9 mRNA in these cells. Interestingly, OHT was even more effective than E 2 in inducing PI-9 mRNA (Figure 5a ). However, raloxifene and ICI 182,780 did not induce PI-9 mRNA, and when present at 100-fold molar excess, blocked induction of PI-9 mRNA by E 2 (Figure 5a ). Western blots showed that OHT and E 2 elicit robust induction of PI-9 protein, with OHT, for unknown reasons, inducing somewhat higher levels of PI-9 than E 2 (Figure 5b ). Consistent with earlier work showing that OHT stabilizes ERa protein and that E 2 downregulates ERa, the level of ERa protein was increased in OHT-treated cells and decreased in E 2 -treated cells (Figure 5c ). In these breast cancer cells containing elevated levels of ERa, OHT was as effective as E 2 in blocking NK92 cell-induced cytolysis (Figure 5d ).
OHT and E 2 induce high levels of PI-9 in ERaHA cells, thereby blocking cytotoxicity induced by NKL cells In ERaHA cells, 100 nM OHT or 10 nM E 2 induce much higher levels of PI-9 than 10 nM E 2 does in MCF-7 cells (Figure 6a ). PI-9 inhibits GrB. The extent to which PI-9 inhibits GrA and other granzymes is unknown. NK92 cells contain primarily GrB. A second NK cell line, NKL cells, contain primarily GrA (Mahrus and Craik, 2005) . GrA induces rapid cell death by a Figure 4 Low concentrations of estradiol efficiently induce PI-9 and protect MCF-7 cells against NK cell-mediated cytotoxicity. (a) At 24 h after adding the indicated concentrations of E 2 to the medium, cell extracts were prepared and 5 mg samples analysed for PI-9 and the calnexin control by Western blot. (b) E 2 (50 pM) protects MCF-7 cells against NK92 cell-induced cytolysis. Cells were maintained for 24 h in no estrogen (Control, filled bars), 50 pM E 2 (open bars) 100 pM E 2 (cross-hatched bars), or 1 nM E 2 (diagonal bars) and assayed for NK92 cell-induced cytotoxicity.
Induction of PI-9 progressively blocks immunosurveillance X Jiang et al pathway distinct from the GrB pathway and can act independently or synergistically with GrB (Lieberman and Fan, 2003) . NK92 cells and NKL cells show similar ability to lyse control MCF-7 cells before estrogen induction. However, while the level of PI-9 in E 2 -treated MCF-7 cells is sufficient to block killing by NK92 cells, NKL cells retain the ability to kill the cells (Figure 6b ). The higher levels of PI-9 induced by OHT and by E 2 in the ERaHA cells (Figure 6a ) results in resistance to cytolysis induced by NKL cells (Figure 6c) . Thus, enhanced induction of PI-9 in cells expressing high levels of ERa increases resistance of the cells to Incubations and assays were as described in Materials and methods. (c) Induction of PI-9 by OHT and by E 2 in ERaHA cells effectively blocks NKL cell-mediated cytotoxicity. Cells were maintained in 1 mg/ml DOX alone (filled bars), DOX plus 10 nM E 2 (open bars), or 100 nM OHT (diagonal bars) and incubated with NKL cells at indicated E/T ratios and assayed for cytotoxicity. Induction of PI-9 progressively blocks immunosurveillance X Jiang et al NK cell-induced cytolysis and has significant functional consequences.
Discussion
Most cases of breast cancer occur in postmenopausal women. The average circulating level of estrogen in postmenopausal women is B50 pM (Meldrum et al., 1981; Lonning et al., 1997) . The induction of PI-9 is maximal at 100 pM E 2 and 70-80% of maximum at 50 pM E 2 . The sensitivity of PI-9 to induction by picomolar concentrations of estrogen may have masked its regulation in an earlier study (Jiang et al., 2006) . Induction of PI-9 by OHT to B20% of maximum did not interfere with the ability of NK92 cells to kill MCF-7 cells. Inducing PI-9 to 70-80% of maximum by 50 pM E 2 was as effective as maximal induction in blocking NK92 cell-mediated killing. Circulating estrogen levels in postmenopausal women may therefore be sufficient to induce PI-9 and blunt the ability of NK cells to kill off target breast cancer cells. The oncogene EGF has diverse effects on cell growth. We describe an effect of EGF on breast cancer cells that does not involve its ability to stimulate cell growth. Although EGF alone does not induce PI-9, it reduces the concentration of E 2 required to induce a protective level of PI-9 to 10 pM.
The concentration of E 2 and the level of intracellular ERa both contribute to the concentration of liganded ERa. Although two E 2 -ER dimers bind the PI-9 ERU in vitro, high concentrations of E 2 -ER are required to occupy the second E 2 -ER binding site (Krieg et al., 2001 ). E 2 induction of PI-9 is amplified in ERaHA cells expressing higher levels of ERa. NKL cells kill E 2 -treated MCF-7 cells, but cannot kill E 2 -treated ERaHA cells expressing high levels of PI-9. As PI-9 inhibits GrB, and NK92 cells contain primarily GrB, the level of PI-9 induced by E 2 may be sufficient to largely protect MCF-7 cells against killing by NK92 cells. However, NKL cells contain more GrA than GrB (Mahrus and Craik, 2005) . The altered protease specificity of GrA compared to GrB suggests PI-9 may be less able to inhibit GrA, and only the high level of PI-9 in E 2 treated ERaHA cells is sufficient to inhibit the GrA in NKL cells. Also, as GrA and GrB kill target cells by different pathways, the levels of active protease required to kill target cells may be different for the two granzymes. These data suggest that estrogen concentration and ER concentration work together to control PI-9 levels and to confer protection against different activators of granzyme-dependent cytotoxicity.
Recently, whether PI-9 expression is sufficient to protect target cells has been questioned. The mouse serpin SPI-6, which is related to PI-9, reportedly does not block CTL-induced killing of target cells without another serpin, SPI-CI, which has no known human homolog (Bots et al., 2005) . The sensitivity of lymphomas to CTL-mediated cytotoxicy was unrelated to PI-9 level (Godal et al., 2006) . In earlier studies high levels of PI-9 were associated with a poor prognosis or therapeutic response in lymphomas and melanomas (ten Berge et al., 2003; van Houdt et al., 2005) . Overexpression of SPI-6 blocked CTL-induced apoptosis in vitro and in vivo (Medema et al., 2001) . Bots et al. (2006b) suggest that using highly activated CTL or NK cells in vitro, may exaggerate the effectiveness of those cells and underestimate the protective ability of PI-9 in vivo. The ability of granzyme M in some CLs to proteolytically cleave and inactivate PI-9 may influence PI-9's ability to block CL-induced cytolysis (Mahrus et al., 2004) . In liver cells, induction of PI-9 by estrogen (Jiang et al., 2006) or by IFNs (Barrie et al., 2004) , partially blocks CTL-and NK cell-induced cytolysis. RNAi knockdown of PI-9 abolishes the ability of estrogen to block cell death induced by CLs in liver cells (Jiang et al., 2006) and in human breast cancer cells (Figure 3b) . Although the estrogen status of the cells was not described, expression of high levels of PI-9 in MCF-7 cells stably transfected to express PI-9 made them more resistant to killing by long-term-activated NK cells (Bird et al., 1998) . Taken together, these studies support the view that increasing levels of PI-9 interfere with the ability of CTLs and NK cells to kill target cells. The level and distribution of granzymes in CLs and of PI-9 in target cells and target cell background, all likely contribute to the extent to which PI-9 expression inhibits CTL-and NK cell-induced cytolysis in vivo.
Although the levels of ERa in Dox-treated ERaHA cells are quite high, a subset of breast cancers exhibits similarly high levels of ERa (Riera et al., 1999; Gritzapis et al., 2003) . Tumors expressing the highest levels of ERa exhibit increased incidence of recurrence and a poor survival prognosis, and often show a reduced response to TAM (Sancho-Garnier et al., 1995; Hupperets et al., 1997; Clarke et al., 2003) . Our observation that OHT effectively induces PI-9 in a cell-based model for this class of tumor, and thereby blocks immune cellmediated killing, provides a molecular mechanism that may help explain the reduced TAM responsiveness of these tumors.
Our studies suggest a reciprocal relationship between estrogen, ER and EGF/EGFR in controlling PI-9 levels and thereby conferring a selective advantage to breast cancer cells by interfering with immunosurveillance. We suggest a graded response in which increasing concentrations of estrogen or higher levels of ERa result in a progressive increase in the resistance of cells to cytotoxicity induced by CLs. In cells that contain moderate concentrations of ERa, that do not overexpress EGFR, higher concentrations of estrogen will be required to block CLs-induced cytotoxicity. Overexpression of EGFR leading to Erk activation reduces the requirement for estrogen. In cells containing high concentrations of ERa, the spectrum of ER agonists is expanded to include TAM and the high levels of PI-9 induced by TAM and estrogen increase the ability of the cancer cells to block CL-induced cytotoxicity.
There is currently strong interest in the relative efficacy in breast cancer therapy and prevention of aromatase inhibitors and the ER ligands, TAM, raloxifene and ICI 182,780 (Faslodex) (Smith and Dowsett, 2003; Gradishar and Cella, 2006; Vogel et al., 2006) . Our identification of a breast cancer model in which OHT, but not raloxifene or ICI/Faslodex induces PI-9, and thereby enables breast cancer cells to evade immune cell-mediated killing provide a novel system in which these pharmaceuticals elicit very different biological outcomes.
Materials and methods
Cell lines and cell culture MCF-7, human breast cancer cells, were cultured in Modified Eagle's Medium (MEM) containing 5% calf serum (Hyclone, Logan, UT, USA). At least 4 days before E 2 treatment, cells were switched to phenol red-free MEM containing 5% charcoal dextran (CD)-treated calf serum. Media were changed on day 2. The tet-inducible MCF-7 cells stably transfected to express additional ERa, ERaHA cells, were grown at 371C in 10% CO 2 in DMEM supplemented with 1 mM sodium pyruvate, 0.5 mg/ml puromycin and 10% fetal bovine serum (FBS). Four days before addition of E 2 or SERMs, ERaHA cells were cultured in DMEM þ 10% six times CD-treated FBS (Fowler et al., 2004 (Fowler et al., , 2006 . NK92 cells (provided by Dr J Miller) were cultured in a-MEM plus 15% FBS, 15% horse serum, supplemented with 200 U/ml IL-2 (PeproTech, Rocky Hill, NJ, USA) and 100 U/ml IL-15 (PeproTech). NKL cells (provided by Dr M Robertson) were cultured in Rosewell Park Memorial Institute (RPMI) 1640 supplemented with 200 U/ml IL-2, 10% FBS. YT cells (provided by Dr C Froelich) were grown in RPMI1640 containing 10% FBS. Cell culture media contained 50 000 IU penicillin and 50 mg streptomycin/l.
QRT-PCR PI-9 mRNA levels were analysed by quantitative real-time reverse transcriptase-polymerase chain reaction (QRT-PCR). Primers were designed using Primer Express software (Applied Biosystems, Foster City, CA, USA). RNA extraction and complementary DNA synthesis were as we recently described (Jiang et al., 2006) . Briefly, QRT-PCR reactions were conducted in 96-well plates using a SYBR Green PCR kit (Applied Biosystems, Foster City, CA, USA), and samples were amplified with Bio-Rad iCycler system. The fold change in expression of each gene was calculated using the DDC t method with actin mRNA as the internal control.
Western blotting
Whole-cell extracts were prepared in radioimmunoprecipitation assay buffer (1 Â phosphate-buffered saline, 1% Nonidet, 0.5%. sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 10 À6 M sodium orthovanadate, 10 mg/ml phenylmethylsulfonyl fluoride and 30 ml/ml aprotinin). For Western blotting, cell lysates containing 5 mg of protein were separated on 10% SDS/polyacrylamide gel electrophoresis gels and transferred to nitrocellulose membranes. Calnexin was used as the loading control. Blots were incubated with the appropriate secondary antibodies, and signals were detected by phosphorImager analysis using ECL Plus (Amersham, Piscataway, NJ, USA).
Cell-mediated cytotoxicity assay It has been shown that time-resolved fluorescence assay produces results similar to the long-established chromium release assay (Blomberg et al., 1996; Mahrus and Craik, 2005) . The assay was carried out following the manufacturer's protocol with a few modifications. Target cells were incubated at 10 6 cells/ml in phenol-red free MEM plus 5% CD-calf serum with BATDA (PerkinElmer, Wellesley, MA, USA) for 10 min at room temperature, followed by four washes. The target cells were then mixed with effector cells at different effector cells/ target cells (E/T) ratios. Cytotoxicity assays were carried out in 96-well round bottom plates containing 10 000 target cells in a total volume of 200 ml/well. The plates were subjected to centrifugation for 30 s at 1000 r.p.m. to facilitate contact between target and effector cells. After incubating for 2 h, supernatant from each reaction (20 ml) were added to 200 ml of the Eu 3 þ solution. Following agitation of the plates for 5 min, time-resolved fluorescence was measured by using an excitation wavelength of 315 nm and an emission wavelength of 623 nm using a PHERAstar (BMG Labtech, Durham, NC, USA) microplate fluorometer. Percent specific lysis was calculated as 100 Â (experimental release À spontaneous release)/(maximum release À spontaneous release).
Transfection of siRNA
The PI-9 siRNA was designed by Dharmacon (Lafayette, CO, USA), and has the sequence 5 0 -CAG UUC CUC UCA ACG UUU AdTdT-3 0 . pGL3 (Luciferase) siRNA was used as a negative control. Cells were plated at 1.5 Â 10 5 cells/well in six-well plates. Transfection was carried out 24 h after plating using 100 nM PI-9 siRNA or pGL3 siRNA using DF1 transfection reagent (Dharmacon, Lafayette, CO, USA) following the manufacturer's protocol. The medium was changed 24 h after transfection, E 2 was added and the cells were maintained for another 24 h, harvested and analysed by Western blotting or by the cytotoxicity assay.
Statistical analysis
The results were reported as mean7s.e.m. Significance levels were determined by Student's t-test analysis.
